45,581 Shares in Indivior PLC $INDV Acquired by Wellington Management Group LLP

Wellington Management Group LLP purchased a new position in shares of Indivior PLC (NASDAQ:INDV) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 45,581 shares of the company’s stock, valued at approximately $1,870,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in INDV. Fuller & Thaler Asset Management Inc. boosted its holdings in shares of Indivior by 101.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock valued at $228,611,000 after acquiring an additional 3,201,639 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Indivior during the fourth quarter worth approximately $82,687,000. State Street Corp increased its holdings in shares of Indivior by 65.5% in the 4th quarter. State Street Corp now owns 4,659,281 shares of the company’s stock valued at $167,175,000 after acquiring an additional 1,844,532 shares during the period. Arrowstreet Capital Limited Partnership acquired a new position in shares of Indivior in the 4th quarter valued at $61,208,000. Finally, Newtyn Management LLC raised its position in Indivior by 61.1% in the 3rd quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock valued at $101,262,000 after purchasing an additional 1,592,982 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Analysts Set New Price Targets

INDV has been the subject of a number of recent research reports. Barclays decreased their price target on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, August 5th. Craig Hallum restated a “buy” rating and issued a $53.00 price objective on shares of Indivior in a research note on Tuesday, August 4th. Weiss Ratings raised shares of Indivior from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, September 4th. Finally, Zacks Research downgraded shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Indivior presently has an average rating of “Moderate Buy” and a consensus target price of $45.17.

Insider Buying and Selling

In other news, insider Christian Heidbreder sold 18,586 shares of the firm’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $41.14, for a total value of $764,628.04. Following the completion of the sale, the insider directly owned 209,337 shares of the company’s stock, valued at $8,612,124.18. This trade represents a 8.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Woodrow D. Anderson purchased 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The stock was acquired at an average price of $35.69 per share, for a total transaction of $53,535.00. Following the completion of the purchase, the chief accounting officer owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. This represents a 5.74% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.74% of the stock is currently owned by insiders.

Indivior Stock Performance

INDV stock opened at $34.51 on Friday. The stock has a market capitalization of $4.07 billion, a PE ratio of 12.37 and a beta of 0.82. The company has a fifty day moving average of $38.29 and a 200-day moving average of $36.05. Indivior PLC has a one year low of $22.22 and a one year high of $42.81.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. The business had revenue of $343.00 million for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. Equities analysts forecast that Indivior PLC will post 3.66 earnings per share for the current fiscal year.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.